Please login to the form below

Not currently logged in
Email:
Password:

lifitegrast

This page shows the latest lifitegrast news and features for those working in and with pharma, biotech and healthcare.

Shire files dry eye drug lifitegrast in Europe

Shire files dry eye drug lifitegrast in Europe

Analysts predict Xiidra could become a $1bn product. Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... Once fully rolled out, analysts have suggested lifitegrast could become a

Latest news

  • Shire licences Parion dry eye drug in $535m deal Shire licences Parion dry eye drug in $535m deal

    All told the deal could be worth up to $535m for North Carolina biotech Parion, while Shire adds to the pipeline behind its recently-approved dry eye disease therapy Xiidra (lifitegrast).

  • Shire launches dry eye drug Xiidra in US Shire launches dry eye drug Xiidra in US

    The Anglo-Irish company is making much of that fact that Xiidra (lifitegrast) - the first in a new class of lymphocyte function-associated antigen 1 (LFA-1) antagonist - is the only

  • FDA finally approves Shire’s potential blockbuster Xiidra FDA finally approves Shire’s potential blockbuster Xiidra

    The only prescription eye drop indicated for the treatment of both signs and symptoms of this condition, Xiidra (lifitegrast ophthalmic solution) is taken twice a day. ... says. Lifitegrast, which was licensed from SARcode Bioscience in 2013, is a

  • FDA deals a big blow to Shire's late-stage pipeline FDA deals a big blow to Shire's late-stage pipeline

    Additional data required before firm can apply for re-approval. Shire suffered a major setback last week when the FDA declined to approve its lifitegrast treatment for dry eye disease, which ... Lifitegrast is a small molecule integrin beta(2) antagonist

  • Shire buys into eyecare specialist Shire buys into eyecare specialist

    Will complement its investigational dry eye drug lifitegrast. Shire has acquired New York-based, privately held Foresight Biotherapeutics for $300m as it looks to add to its eyecare portfolio. . ... It is highly synergistic with the planned lifitegrast

More from news
Approximately 3 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    Shire's second acquisition of the month was also in the field of ophthalmology bringing SARcode Bioscience for $160m plus additional milestones with its phase III stage product Lifitegrast for dry ... Lifitegrast is a small-molecule integrin antagonist

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wordbird

Wordbird is a healthcare communications agency with creative, compelling copy at its heart....

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics